Our latest products
-
SORACAP – 200MG Sorafenib
₹2,800.00₹2,000.00Sorafenib is an oral targeted kinase inhibitor used to treat advanced renal cell carcinoma (kidney cancer), unresectable hepatocellular carcinoma (liver cancer), and radioactive iodine-resistant differentiated thyroid cancer.
How to Take It
- Form & Dosage: It is available as a 200 mg tablet. The standard dosage is typically 400 mg (two tablets) taken twice daily.
- Administration: Tablets should be swallowed whole with a glass of water. It is generally recommended to take sorafenib either on an empty stomach or with a low-to-moderate-fat meal, as a high-fat meal can reduce the drug’s absorption and efficacy.
Common Side Effects
Patients taking sorafenib may experience several side effects. Common ones include:- Dermatological: Hand-foot skin reaction (redness, pain, or peeling on the palms and soles), rash, and dry skin.
- Gastrointestinal: Diarrhea, nausea, vomiting, and decreased appetite.
- Systemic: Fatigue, weakness, and weight loss.
- Cardiovascular: High blood pressure (hypertension).
-
IMACAP-100MG Imatinib
₹1,400.00₹1,000.00Imatinib is a prescription medication used to treat Acute Lymphoblastic Leukemia, Myelodysplastic/Myeloproliferative Disease, Hypereosinophilic Syndrome and/or Chronic Eosinophilic Leukemia, Chronic Myeloid Leukemia Philadelphia-Chromosome-Positive, Dermatofibrosarcoma Protuberans, Mastocytosis, and Gastrointestinal Stromal Tumors.
-
LENVACAP 4MG – Lenvatinib
₹1,500.00₹1,300.00LENVACAP® (lenvatinib), a prescription medicine that may help treat people with certain kinds of cancer.
-
OSIM-80 Osimertinib
₹2,100.00OSIM-80 (Osimertinib)/ Azd9291 is kinase inhibitor of the epidermal growth factor receptor (EGFR).
-
OSIM-40 Osimertinib
₹1,500.00OSIM-40 Osimertinib is kinase inhibitor of the epidermal growth factor receptor (EGFR).
-
DASA-20 Dasatinib
₹12,000.00DASA-20 Dasatinib is a medicine that targets specific proteins in cancer cells and stops the cancer cells
from growing. It is used to treat some kinds of leukemia.










